Evidence Hub

Suspected Drug-Induced Liver Injury Associated With Ceftriaxone: A Case Report

Allison D Zettwoch, O. Okobi, M. Millán, Angelica Perez Fonte, Raphael S Figueroa, Tolulope A. Fatuki, Raul J. De la Vega, Sergio Hernandez Borges et al.

Cureus, 2025

1 citation

Abstract

An 85-year-old female patient with multiple comorbidities, including Parkinson's disease, hyperthyroidism, congestive heart failure, and Alzheimer's, presented with dyspnea, weakness, and cough. She was found to have new-onset atrial fibrillation and a left frontal lobe infarct. Initially treated with levofloxacin and then azithromycin, she later developed right lung infiltrates, and ceftriaxone 2g IV daily was initiated. Within 48 hours, liver enzymes aspartate aminotransferase (AST) and alanine transaminase (ALT) rose markedly (from 11/26 to 452/415 U/L). We promptly discontinued ceftriaxone in response and considered alternative antibiotics. The multidisciplinary team opted for supportive management with daily liver function monitoring, resulting in gradual normalization of transaminases. This case highlights the importance of prompt drug discontinuation, use of structured drug-induced liver injury (DILI) assessment tools, and adherence to geriatric prescribing guidelines.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free